Table 1 Demographic, clinical and histological characteristics of the patient cohort
Treatment group | ||
|---|---|---|
DMARDs | RTX | |
Number of patients | 22 | 19 |
Age (years) | 43 (30 to 56) | 40 (27 to 53) |
Sex (female) | 22 (100%) | 18 (94.7%) |
Disease duration (months) | 14 (7 to 21) | 13 (6 to 20) |
Parotid gland enlargement | 18 (81.8%) | 16 (84.2%) |
Cutaneous vasculitis | 2 (9.0%) | 3 (15.7%) |
Pulmonary involvement | 1 (4.5%) | 1 (5.2%) |
Neurological involvement | 3 (13.6%) | 2 (10.5%) |
Renal involvement | 0 (0%) | 0 (0%) |
Autoimmune cytopenia | 7 (31.8%) | 8 (42.1%) |
Myositis | 0 (0%) | 0 (0%) |
Arthritis. | 11 (50%) | 9 (47.3%) |
Lymphadenopathy | 15 (68.1%) | 17 (89.4%) |
ESSDAI | 19.8 (6 to 41) | 20.3 (6 to 41) |
Prednisonea | 22 (12.5) | 19 (12.5) |
DMARDs (HCQ/MTX/CsA) | 22 (15/13/8) | 0 (0/0/0) |
Chisholm and Mason score ≥3 | 22 | 19 |
Focus score | 1.8 (1 to 3.3) | 1.8 (1 to 3.4) |